

Harald Hampel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7609799/harald-hampel-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

462
papers

50,839
citations

97
h-index

216
g-index

550
ext. papers

60,292
ext. citations

6.7
avg, IF

7.04
L-index

#	Paper	IF	Citations
462	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
461	Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation.. <i>Alzheimerls and Dementia</i> , 2022 ,	1.2	1
460	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
459	Toward Noninvasive Brain Stimulation 2.0 in Alzheimer's Disease.. <i>Ageing Research Reviews</i> , 2021 , 75, 101555	12	2
458	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 748198	5.3	1
457	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimerls and Dementia</i> , 2021 , 17, 1528-1553	1.2	12
456	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimerls and Dementia</i> , 2021 ,	1.2	6
455	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021 , 185, 108081	5.5	12
454	The β Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 745-756	7.9	107
453	Aptamer prediction of brain amyloid- β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021 , 16, e0243902	3.7	1
452	MiRNA-15b and miRNA-125b are associated with regional A β PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021 , 11, 78	8.6	6
451	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021 , 18, 27-48	4.2	3
450	Plasma β Secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimerls and Dementia</i> , 2021 , 17, 629-640	1.2	4
449	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021 , 103, 78-97	5.6	3
448	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021 , 17, 580-589	15	25
447	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 949-967	4.3	0
446	Omic sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021 , 69, 101346	12	17

445	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63
444	Association of plasma A β ₄₀ /A β ₄₂ ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 107, 57-69	5.6	1
443	Association of β Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.. <i>Neurology</i> , 2021 ,	6.5	1
442	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041753	1.2	
441	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041792	1.2	
440	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046014	1.2	
439	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046105	1.2	
438	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 1157-1166	4.3	9
437	Exercise benefits on Alzheimer's disease: State-of-the-science. <i>Ageing Research Reviews</i> , 2020 , 62, 101108	10.8	53
436	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020 , 91, 88-111	5.6	13
435	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 93, 98-108	5.6	10
434	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 421-441	3.8	19
433	Early Detection of Mild Cognitive Impairment (MCI) in Primary Care. <i>Journal of Prevention of Alzheimer's Disease</i> , 2020 , 7, 165-170	3.8	21
432	Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting. <i>Journal of Prevention of Alzheimer's Disease</i> , 2020 , 7, 171-178	3.8	12
431	Successful aging: insights from proteome analyses of healthy centenarians. <i>Aging</i> , 2020 , 12, 3502-3515	5.6	18
430	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 88, 83-90	5.6	3
429	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020 , 94, e30-e41	6.5	13
428	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. <i>Aging Clinical and Experimental Research</i> , 2020 , 32, 817-826	4.8	1

427	Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. <i>journal of prevention of Alzheimer's disease, The</i> , 2020 , 7, 158-164	3.8	8
426	Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
425	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020 , 17, 543-559	4.2	6
424	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020 , 131, 2716-2731	4.3	3
423	Association of plasma YKL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
422	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020 , 90, 43-59	5.6	12
421	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020 , 14, 585432	5.1	28
420	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 147	9	8
419	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020 , 57, 4667-4691	6.2	14
418	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	5
417	The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline. <i>journal of prevention of Alzheimer's disease, The</i> , 2020 , 7, 294-298	3.8	3
416	Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 151-164	2.3	21
415	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020 , 85, 58-73	5.6	59
414	A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12613	6	11
413	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 456	8.4	87
412	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology, The</i> , 2019 , 18, 1034-1044	24.1	45
411	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019 , 83, 42-53	5.6	23
410	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019 , 77, 112-127	5.6	12

409	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 615-629	4.3	28
408	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 613-623	3.8	8
407	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019 , 16, 593-600	4.2	20
406	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 764-775	1.2	86
405	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 940-950	1.2	31
404	Commentary: Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019 , 6, 182-184	3.8	1
403	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019 , 10, 310	5.6	23
402	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1-24	4.3	48
401	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019 , 181, 101662	10.9	26
400	Brain A β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1274-1285	1.2	9
399	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019 , 21, 177-191	5.7	13
398	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
397	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019 , 15, 465-476	1.2	127
396	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019 , 290, 167-176	20.5	15
395	Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019 , 6, 2-15	3.8	61
394	Cognitive and neuroimaging features and brain β amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , 2018 , 17, 335-346	24.1	113
393	Magnetic resonance imaging-based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. <i>Alzheimer's and Dementia</i> , 2018 , 14, 976-978	1.2	1
392	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018 , 130, 331-365	10.2	60

391	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β -total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018 , 14, 492-501	1.2	71
390	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β -positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
389	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S47-S105	4.3	84
388	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2018 , 83, 447-455	7.9	62
387	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
386	Association of cerebrospinal fluid β -synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
385	Reply: Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018 , 141, e69	11.2	
384	Sex differences in Alzheimer disease - the gateway to precision medicine. <i>Nature Reviews Neurology</i> , 2018 , 14, 457-469	15	280
383	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1204-1215	1.2	40
382	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 67	5.3	18
381	Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. <i>PLoS ONE</i> , 2018 , 13, e0190212	3.7	6
380	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018 , 50, 31-51	8.9	29
379	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. <i>Methods in Molecular Biology</i> , 2018 , 1750, 31-66	1.4	23
378	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018 , 1750, 139-155	1.4	10
377	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018 , 17, 435-443	5.3	13
376	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
375	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , 2018 , 32, 75-86	2.5	33
374	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A β -42, TOTAL-TAU, PHOSPHORYLATED-TAU, NFL, NEUROGRANIN, AND YKL-40 2018 , 14, P1154-P1155		1

373	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL 2018 , 14, P1461-P1462		
372	P1-627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT 2018 , 14, P581-P582		
371	P3-411: CLINICAL SIGNIFICANCE OF IN-VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P1262-P1263		
370	P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS 2018 , 14, P762-P762		
369	P3-248: STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER'S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN 2018 , 14, P1168-P1168		
368	P4-027: EVIDENCE FOR COGNITIVE COMPENSATION IN EARLY AMYLOIDOSIS IN HIGH-PERFORMING HEALTHY ELDERLY AT RISK FOR ALZHEIMER'S DISEASE 2018 , 14, P1443-P1444		
367	O4-07-04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN 2018 , 14, P1419-P1420		
366	O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P1036-P1037		
365	P4-098: ASSOCIATION BETWEEN COGNITIVE RESERVE AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE 2018 , 14, P1474-P1475		
364	P2-397: REDUCED BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO MEN 2018 , 14, P855-P856		
363	P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P767-P768		
362	P2-249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P768-P769		
361	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018 , 136, 821-853	14.3	236
360	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018 , 14, 639-652	15	257
359	P2-355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P824-P825		
358	P1-431: APOE-DEPENDENT LONGITUDINAL CHANGES IN DEFAULT MODE NETWORK FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P474-P474		1
357	Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors. <i>Frontiers in Neurology</i> , 2018 , 9, 642	4.1	18
356	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018 , 141, 1917-1933	11.2	492

355	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1126-1136	1.2	12
354	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 47-57	4.3	44
353	The European DTI Study on Dementia - A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017 , 144, 305-308	7.9	15
352	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 543-555	4.3	7
351	Free and Cued Selective Reminding Test - accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017 , 13, 913-923	1.2	45
350	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. <i>Neuropsychology Review</i> , 2017 , 27, 245-257	7.7	61
349	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017 , 14, 285-299	4.2	49
348	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017 , 13, 454-467	1.2	49
347	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 993-1003	1.2	35
346	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , 2017 , 20, 107-118	3.1	84
345	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017 , 1598, 101-115	1.4	11
344	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017 , 108, 355-360	4.4	38
343	Disrupted white matter structural networks in healthy older adult APOE $\epsilon 4$ carriers - An international multicenter DTI study. <i>Neuroscience</i> , 2017 , 357, 119-133	3.9	23
342	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017 , 55, 177-189	5.6	14
341	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 33-40	5.6	19
340	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1327-1334	4.3	28
339	Preclinical effects of APOE $\epsilon 4$ on cerebrospinal fluid A β 2 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 87	9	16
338	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 101	9	31

337	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 11706	4.9	53
336	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017 , 49, 1373-1384	36.3	508
335	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. <i>Trends in Neurosciences</i> , 2017 , 40, 469-480	13.3	25
334	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017 , 13, 45-58 ^{1.2}	1.2	163
333	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017 , 13, 296-311	1.2	245
332	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 59-71	1.2	70
331	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2017 , 19, 154-160	4.6	10
330	[IC-P-152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING-STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHT-PRE AD STUDY 2017 , 13, P114-P115		
329	[P1B88]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS 2017 , 13, P414-P415		
328	[P1B41]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING-STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHT-PRE-AD STUDY 2017 , 13, P451-P452		
327	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 577-583	4.3	1
326	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 151-161	4.3	4
325	Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 753-762	4.3	27
324	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. <i>Neurobiology of Aging</i> , 2017 , 57, 143-152	5.6	13
323	Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2016 , 1303, 49-67	1.4	29
322	Mechanical stress related to brain atrophy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 11-20	1.2	19
321	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016 , 21, 108-17	15.1	175
320	Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 867-73	4.3	13

319	Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 1319-1331	4.3	6
318	Dementia: The rising global tide of cognitive impairment. <i>Nature Reviews Neurology</i> , 2016 , 12, 131-2	15	18
317	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
316	The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 786-95	1.2	21
315	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016 , 249, 84-90	2.9	7
314	Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. <i>Neuropharmacology</i> , 2016 , 108, 128-35	5.5	12
313	The Latent Dementia Phenotype Is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 547-60	4.3	17
312	Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. <i>Journal of Prevention of Alzheimer's Disease</i> , 2016 , 3, 68-74	3.8	25
311	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016 , 87, 539-47	6.5	710
310	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 3, 27-34	5.2	35
309	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016 , 5, 383-387	8.2	19
308	Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease. <i>Annals of Neurology</i> , 2016 , 79, 739-747	9.4	42
307	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015 , 138, 1327-38	11.2	211
306	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. <i>Alzheimer's and Dementia</i> , 2015 , 11, 111-25	1.2	137
305	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	15.2	86
304	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences--part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 5-18	5.1	19
303	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
302	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015 , 47, 445-7	36.3	222

301	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15	1.2	87
300	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 83-105	4.3	53
299	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 58-69	1.2	271
298	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 205, 1-10	5.1	19
297	Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 403-10	4.3	95
296	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 793-804	4.3	20
295	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 199-209	4.3	21
294	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S171-91	4.3	29
293	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 291-317	4.3	61
292	Fully automated atlas-based hippocampal volumetry for detection of Alzheimer's disease in a memory clinic setting. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 183-93	4.3	25
291	Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015 , 12, 69-79	3	19
290	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015 , 11, 549-60	1.2	159
289	Cognitive Rehabilitation in Alzheimer's Disease - A Conceptual and Methodological Review. <i>Journal of Prevention of Alzheimer's Disease</i> , 2015 , 2, 142-152	3.8	7
288	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014 , 13, 614-29	24.1	1985
287	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , 2014 , 261, 1234-43	5.5	29
286	The ϵ genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 401-4	1.2	22
285	Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 687-700	4.3	111
284	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 381-92	1.2	53

283	Standardization of MRI and Amyloid Imaging 2014 , 131-156		0
282	Fractional anisotropy changes in Alzheimer's disease depend on the underlying fiber tract architecture: a multiparametric DTI study using joint independent component analysis. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 69-83	4.3	57
281	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
280	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014 , 88, 426-49	6	84
279	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. <i>Molecular Psychiatry</i> , 2014 , 19, 148-9	15.1	26
278	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA 2014 , 10, P541-P542		1
277	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA 2014 , 10, P37-P37		
276	Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. <i>PLoS ONE</i> , 2014 , 9, e100812	3.7	31
275	S3-01-02: SCREENING FOR AD: WHY AND HOW? 2014 , 10, P200-P200		
274	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <i>JAMA Psychiatry</i> , 2014 , 71, 1183-91	14.5	65
273	Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 877-86	4.3	21
272	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 115-312		196
271	Biomarkers in amyloid- β immunotherapy trials in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2014 , 39, 189-201	8.7	54
270	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. <i>PLoS ONE</i> , 2014 , 9, e94661	3.7	90
269	The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. <i>Journal of Prevention of Alzheimer's Disease</i> , 2014 , 1, 181-202	3.8	39
268	EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. <i>Journal of Prevention of Alzheimer's Disease</i> , 2014 , 1, 110-116	3.8	2
267	Neural adaptation to thin and fat bodies in the fusiform body area and middle occipital gyrus: an fMRI adaptation study. <i>Human Brain Mapping</i> , 2013 , 34, 3233-46	5.9	31
266	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2013 , 101-102, 1-17	10.9	88

265	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. <i>Journal of Nutrition, Health and Aging</i> , 2013 , 17, 54-63	5.2	24
264	Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 345-52	5.1	79
263	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013 , 45, 1452-8	36.3	2714
262	Alzheimer disease: from biomarkers to diagnosis. <i>Revue Neurologique</i> , 2013 , 169, 744-51	3	15
261	Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 11	9	4
260	Variant of TREM2 associated with the risk of Alzheimer's disease. <i>New England Journal of Medicine</i> , 2013 , 368, 107-16	59.2	1603
259	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013 , 34, 2003-13	5.6	69
258	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
257	Biological and methodical challenges of blood-based proteomics in the field of neurological research. <i>Progress in Neurobiology</i> , 2013 , 101-102, 18-34	10.9	38
256	Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 324	64.1	48
255	Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 33 Suppl 1, S329-47	4.3	16
254	Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 399-424	7	108
253	The association between APOE ϵ 4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 241-6	4.3	6
252	Single-domain amnesic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 1-19	2.6	32
251	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological Medicine</i> , 2013 , 43, 911-20	6.9	72
250	A new sandwich immunoassay for detection of the β secretase cleaved, soluble amyloid- β protein precursor in cerebrospinal fluid and serum. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 667-78	4.3	9
249	APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 389-401	4.3	13
248	Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 6416-25	3.3	6

247	Amyloid- β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. <i>Journal of Alzheimer's Disease</i> , 2013 , 33 Suppl 1, S79-86	4.3	32
246	Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data. <i>PLoS ONE</i> , 2013 , 8, e64925	3.7	77
245	Imaging epigenetics in Alzheimer's disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 6393-415	3.3	31
244	Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0) 2013 , 1-24		
243	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012 , 119, 39-52	4.3	54
242	Interhemispheric hypoconnectivity in schizophrenia: fiber integrity and volume differences of the corpus callosum in patients and unaffected relatives. <i>NeuroImage</i> , 2012 , 59, 926-34	7.9	88
241	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012 , 8, 312-36	1.2	92
240	Association of microstructural white matter abnormalities with cognitive dysfunction in geriatric patients with major depression. <i>Psychiatry Research - Neuroimaging</i> , 2012 , 203, 194-200	2.9	25
239	Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 466-78	5.6	179
238	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012 , 33, 1203-14	5.6	278
237	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 1599-608	5.6	38
236	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012 , 33, 2272-81	5.6	72
235	Cognitive and behavioural effects of physical exercise in psychiatric patients. <i>Progress in Neurobiology</i> , 2012 , 96, 46-68	10.9	114
234	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012 , 6, 419-30	2.3	230
233	Cortical-basal ganglia imbalance in schizophrenia patients and unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2012 , 138, 120-7	3.6	34
232	Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. <i>Schizophrenia Research</i> , 2012 , 140, 129-35	3.6	54
231	Amyloid- β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 171-6	4.3	78
230	Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. <i>PLoS ONE</i> , 2012 , 7, e32441	3.7	74

229	Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. <i>PLoS ONE</i> , 2012 , 7, e48895;7	129
228	Subjective memory complaints in community dwelling healthy older people: the influence of brain and psychopathology. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 836-43	3.9 30
227	Treatment options for tauopathies. <i>Current Treatment Options in Neurology</i> , 2012 , 14, 126-36	4.4 32
226	Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. <i>Journal of Nutrition, Health and Aging</i> , 2012 , 16, 346-8	5.2 9
225	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. <i>Journal of Nutrition, Health and Aging</i> , 2012 , 16, 339-45	5.2 31
224	Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 341-50	5.1 25
223	Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. <i>Current Alzheimer Research</i> , 2012 , 9, 241-7	3 13
222	Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. <i>Journal of Biological Chemistry</i> , 2012 , 287, 12858-66	5.4 22
221	The role of variation at AβP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 377-87	4.3 47
220	Diagnostic Tools: Fluid Biomarkers for Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012 , 71-79	
219	Patterns of autobiographical memory in bipolar disorder examined by psychometric and functional neuroimaging methods. <i>Journal of Nervous and Mental Disease</i> , 2012 , 200, 296-304	1.8 14
218	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012 , 80-114	
217	Anatomical MRI and DTI in the diagnosis of Alzheimer's disease: a European multicenter study. <i>Journal of Alzheimer's Disease</i> , 2012 , 31 Suppl 3, S33-47	4.3 69
216	Validation of AclarusDx's blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 169-81	4.3 44
215	Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. <i>International Psychogeriatrics</i> , 2012 , 24 Suppl 1, S10-7	3.4 22
214	Metabolite profiling of Alzheimer's disease cerebrospinal fluid. <i>PLoS ONE</i> , 2012 , 7, e31501	3.7 122
213	White matter differences between healthy young ApoE4 carriers and non-carriers identified with tractography and support vector machines. <i>PLoS ONE</i> , 2012 , 7, e36024	3.7 17
212	Sexual dimorphism in healthy aging and mild cognitive impairment: a DTI study. <i>PLoS ONE</i> , 2012 , 7, e37037	3.7 19

211	Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, e1492-8	4.6	37
210	Diagnostik und Therapie demenzieller Syndrome (ICD-10 F0) 2012 , 1-20		
209	Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. <i>Biological Psychiatry</i> , 2011 , 70, 145-51	7.9	18
208	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. <i>Molecular Diagnosis and Therapy</i> , 2011 , 15, 83-102	4.5	24
207	Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 373-81	4.3	41
206	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <i>Trends in Neurosciences</i> , 2011 , 34, 430-42	13.3	235
205	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011 , 95, 579-93	10.9	100
204	Biomarker-based dissection of neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2011 , 95, 520-34	10.9	66
203	Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. <i>Progress in Neurobiology</i> , 2011 , 95, 547-56	10.9	30
202	Discovery and development of integrative biological markers for schizophrenia. <i>Progress in Neurobiology</i> , 2011 , 95, 686-702	10.9	25
201	Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. <i>Progress in Neurobiology</i> , 2011 , 95, 557-69	10.9	45
200	Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2011 , 95, 570-8	10.9	18
199	Staging Alzheimer's disease progression with multimodality neuroimaging. <i>Progress in Neurobiology</i> , 2011 , 95, 535-46	10.9	55
198	Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. <i>Progress in Neurobiology</i> , 2011 , 95, 491-5	10.9	34
197	Perspectives of worldwide translational biomarker research in neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2011 , 95, 496-7	10.9	4
196	Biomarkers for major depression and its delineation from neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2011 , 95, 703-17	10.9	30
195	Prevention trials in Alzheimer's disease: an EU-US task force report. <i>Progress in Neurobiology</i> , 2011 , 95, 594-600	10.9	52
194	Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. <i>Progress in Neurobiology</i> , 2011 , 95, 498-500	10.9	27

193	The role of genetics for biomarker development in neurodegeneration. <i>Progress in Neurobiology</i> , 2011 , 95, 501-4	10.9	20
192	The future of Alzheimer's disease: the next 10 years. <i>Progress in Neurobiology</i> , 2011 , 95, 718-28	10.9	156
191	Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2011 , 95, 517-9	10.9	21
190	Impact of employment status and work-related factors on risk of completed suicide. A case-control psychological autopsy study. <i>Psychiatry Research</i> , 2011 , 190, 265-70	9.9	83
189	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 474-485.e4	1.2	139
188	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011 , 7, 386-395.e6	1.2	291
187	CALHM1 P86L polymorphism modulates CSF A β levels in cognitively healthy individuals at risk for Alzheimer's disease. <i>Molecular Medicine</i> , 2011 , 17, 974-9	6.2	24
186	Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. <i>PLoS ONE</i> , 2011 , 6, e21745	3.7	93
185	Effects of a newly developed cognitive intervention in amnesic mild cognitive impairment and mild Alzheimer's disease: a pilot study. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 679-94	4.3	96
184	Effects of a 6-month cognitive intervention program on brain metabolism in amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 695-706	4.3	25
183	Using diffusion tensor imaging and mixed-effects models to investigate primary and secondary white matter degeneration in Alzheimer's disease and mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 667-82	4.3	31
182	Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 26 Suppl 3, 337-48	4.3	38
181	Common capacity-limited neural mechanisms of selective attention and spatial working memory encoding. <i>European Journal of Neuroscience</i> , 2011 , 34, 827-38	3.5	28
180	Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease study. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 2273-81	5.6	51
179	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011 , 43, 429-35	36.3	1421
178	Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study. <i>Psychiatry Research - Neuroimaging</i> , 2011 , 194, 363-371	2.9	84
177	Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. <i>Lancet Neurology</i> , 2011 , 10, 598-601	24.1	20
176	Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2011 , 6, 69	19	59

175	The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011 , 32, 1349-62	5.9	87
174	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: effect of different processing and analysis approaches on sample sizes. <i>World Journal of Biological Psychiatry</i> , 2011 , 12 Suppl 1, 109-13	3.8	6
173	Regional differences in effects of APOE ϵ 4 on cognitive impairment in non-demented subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 135-42	2.6	13
172	Amyloid β and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 367-74	5.9	51
171	Left anterior temporal lobe sustains naming in Alzheimer's dementia and mild cognitive impairment. <i>Current Alzheimer Research</i> , 2011 , 8, 893-901	3	16
170	Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 448-57	4.6	42
169	Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 556-63	4.6	23
168	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010 , 15, 138-45	15.1	134
167	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 560-74	64.1	446
166	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. <i>PLoS ONE</i> , 2010 , 5, e13950	3.7	276
165	Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 243-53	3.1	17
164	Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2010 , 10, 667-90	3.8	49
163	Galantamine for Alzheimer's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 345-54	5.5	51
162	Alzheimer disease: functional abnormalities in the dorsal visual pathway. <i>Radiology</i> , 2010 , 254, 219-26	20.5	37
161	Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. <i>Biological Psychiatry</i> , 2010 , 67, 161-7	7.9	142
160	Functional representation of olfactory impairment in early Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 581-91	4.3	52
159	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 131-44	15	1328
158	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. <i>Experimental Neurology</i> , 2010 , 223, 334-46	5.7	120

157	Age-related networks of regional covariance in MRI gray matter: reproducible multivariate patterns in healthy aging. <i>NeuroImage</i> , 2010 , 49, 1750-9	7.9	82
156	Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. <i>NeuroImage</i> , 2010 , 50, 162-74	7.9	230
155	Cognitive intervention in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 508-17	15	117
154	White matter microstructure underlying default mode network connectivity in the human brain. <i>NeuroImage</i> , 2010 , 49, 2021-32	7.9	155
153	Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 507-22	4.3	134
152	Diagnostic utility of novel MRI-based biomarkers for Alzheimer's disease: diffusion tensor imaging and deformation-based morphometry. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 477-90	4.3	31
151	Altered brain activation during a verbal working memory task in subjects with amnesic mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 103-18	4.3	76
150	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 127-37	5.1	43
149	Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2010 , 221, 62-7	3.5	13
148	FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2010 , 44, 462-9	5.2	36
147	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 182, 244-50	2.9	39
146	The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 183, 44-51	2.9	24
145	Blood-based biomarkers of microvascular pathology in Alzheimer's disease. <i>Experimental Gerontology</i> , 2010 , 45, 75-9	4.5	95
144	Total and phosphorylated tau protein as biological markers of Alzheimer's disease. <i>Experimental Gerontology</i> , 2010 , 45, 30-40	4.5	258
143	Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010 , 5, 2	19	66
142	Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 27, 404-17	2.6	61
141	Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009 , 44, 579-85	4.5	55
140	Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , 2009 , 30, 2098-119	5.9	72

139	The problem of being a paradigm: the emergence of neural stem cells as example for Kuhnian revolution in biology or misconception of the scientific community?. <i>Poiesis & Praxis</i> , 2009 , 6, 3-11		1
138	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009 , 41, 1088-93	36.3	2018
137	IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. <i>Stem Cells</i> , 2009 , 27, 478-88	5.8	204
136	Assessing neuronal networks: understanding Alzheimer's disease. <i>Progress in Neurobiology</i> , 2009 , 89, 125-33	10.9	92
135	Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. <i>Biological Psychiatry</i> , 2009 , 65, 979-84	7.9	37
134	Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2009 , 69, 8-12	2	52
133	Early risk assessment for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009 , 5, 182-96	1.2	33
132	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
131	Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. <i>CNS Neuroscience and Therapeutics</i> , 2009 , 15, 358-74	6.8	113
130	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , 2009 , 8, 619-27	24.1	473
129	Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 147-56	1.7	30
128	White matter microstructure in relation to education in aging and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 571-83	4.3	69
127	Anticonvulsants in the treatment of aggression in the demented elderly: an update. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2009 , 5, 14	3.2	13
126	Biological markers for early detection and pharmacological treatment of Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009 , 11, 141-57	5.7	31
125	Lithium Trial in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 922-931	4.6	208
124	Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 922-31	4.6	120
123	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: an fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2008 , 163, 248-59	2.9	38
122	Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. <i>Neurobiology of Aging</i> , 2008 , 29, 23-30	5.6	212

121	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. <i>Neurobiology of Aging</i> , 2008 , 29, 812-8	5.6	84
120	Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008 , 4, 38-48	1.2	349
119	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. <i>Alzheimer's and Dementia</i> , 2008 , 4, 255-64	1.2	35
118	Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. <i>International Psychogeriatrics</i> , 2008 , 20, 67-76	3.4	53
117	Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. <i>Brain</i> , 2008 , 131, 1252-8	11.2	99
116	Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 69-75	3.8	11
115	Diagnostic usefulness of cognitive auditory event-related p300 subcomponents in patients with Alzheimer's disease?. <i>Journal of Clinical Neurophysiology</i> , 2008 , 25, 147-52	2.2	47
114	Novel MRI techniques in the assessment of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35 Suppl 1, S58-69	8.8	61
113	Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. <i>Journal of Neurochemistry</i> , 2007 , 101, 1053-9	6	185
112	Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2007 , 189, 169-74	3.5	12
111	Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007 , 257, 330-6	5.1	20
110	Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer's disease: a diffusion tensor imaging and voxel-based morphometry study. <i>Cerebral Cortex</i> , 2007 , 17, 2276-82	5.1	67
109	No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. <i>Brain</i> , 2007 , 130, e82	11.2	49
108	White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. <i>Radiology</i> , 2007 , 243, 483-92	20.5	183
107	Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. <i>Archives of General Psychiatry</i> , 2007 , 64, 718-26		166
106	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. <i>Brain</i> , 2007 , 130, 1745-58	11.2	41
105	Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. <i>Neuroscience Letters</i> , 2007 , 418, 186-9	3.3	14
104	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007 , 34, 985-95.9		144

103	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. <i>NeuroImage</i> , 2007 , 38, 13-24	7.9	160
102	Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. <i>Psychopharmacology</i> , 2006 , 187, 86-94	4.7	51
101	Response to Boban et al: computer-assisted 3D reconstruction of the nucleus basalis complex, including the nucleus subputaminalis (Ayala's nucleus). <i>Brain</i> , 2006 , 129, E43-E43	11.2	12
100	Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. <i>Brain</i> , 2006 , 129, 1113-24	11.2	192
99	CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. <i>Brain</i> , 2006 , 129, 3035-41	11.2	451
98	Biomarkers in the diagnosis of Alzheimer's disease: are we ready?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006 , 19, 172-9	3.8	44
97	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 1472-80	5.9	100
96	Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. <i>CNS Drugs</i> , 2006 , 20, 311-25	6.7	42
95	Mild cognitive impairment. <i>Lancet, The</i> , 2006 , 367, 1262-70	40	1703
94	Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. <i>Life Sciences</i> , 2006 , 79, 1307-11	6.8	39
93	International quality control survey of neurochemical dementia diagnostics. <i>Neuroscience Letters</i> , 2006 , 409, 1-4	3.3	91
92	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006 , 27, 10-5	5.6	60
91	Regional network of magnetic resonance imaging gray matter volume in healthy aging. <i>NeuroReport</i> , 2006 , 17, 951-6	1.7	64
90	The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006 , 96, 635-44	6	105
89	A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. <i>European Radiology</i> , 2006 , 16, 1096-103	8	29
88	Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. <i>Behavior Genetics</i> , 2006 , 36, 405-15	3.2	106
87	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. <i>Journal of Neurology</i> , 2006 , 253, 794-800	5.5	86
86	Frontal diaschisis in a German case of fatal familial insomnia. <i>Journal of Neurology</i> , 2006 , 253, 1510-2	5.5	2

85	Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2005 , 62, 770-3		137
84	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. <i>Brain</i> , 2005 , 128, 2626-44	11.2	182
83	Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. <i>NeuroImage</i> , 2005 , 28, 980-95	7.9	536
82	Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. <i>Neuroscience Letters</i> , 2005 , 391, 48-50	3.3	24
81	Reliable manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic resonance images of healthy subjects. <i>Brain Research Protocols</i> , 2005 , 14, 135-45		25
80	Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. <i>Biological Psychiatry</i> , 2005 , 57, 813-6	7.9	58
79	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005 , 255, 269-78	5.1	50
78	Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2005 , 8, 801-6	1.3	52
77	Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. <i>Cerebral Cortex</i> , 2005 , 15, 995-1001	5.1	333
76	Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 20, 367-74	2.6	12
75	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336
74	Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 17, 350-4	2.6	49
73	Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. <i>Brain</i> , 2004 , 127, 811-24	11.2	115
72	Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. <i>Brain</i> , 2004 , 127, 2629-35	11.2	89
71	Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. <i>Journal of Neuroscience</i> , 2004 , 24, 1760-71	6.6	148
70	Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2004 , 9, 705-10	15.1	240
69	Targets of antidementive therapy: drugs with a specific pharmacological mechanism of action. <i>Current Pharmaceutical Design</i> , 2004 , 10, 223-9	3.3	6
68	CSF tau and amyloid as biomarkers for mild cognitive impairment. <i>Dialogues in Clinical Neuroscience</i> , 2004 , 6, 379-90	5.7	16

67	Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003 , 10, 1-6	2.7	75
66	Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. <i>Brain</i> , 2003 , 126, 1935-9	11.2	105
65	Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. <i>American Journal of Psychiatry</i> , 2003 , 160, 376-9	11.9	70
64	Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. <i>American Journal of Psychiatry</i> , 2003 , 160, 1870-8	11.9	83
63	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 44-8	5.1	23
62	Immunotherapy for Alzheimer's disease. <i>Lancet Neurology</i> , 2003 , 2, 215-20	24.1	89
61	CSF markers for incipient Alzheimer's disease. <i>Lancet Neurology</i> , 2003 , 2, 605-13	24.1	969
60	Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 2003 , 54, 263-7	9.4	72
59	Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. <i>Journal of the American Geriatrics Society</i> , 2003 , 51, 578-9	5.6	50
58	Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. <i>Experimental Neurology</i> , 2003 , 183, 74-80	5.7	103
57	Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. <i>Neuroscience Letters</i> , 2003 , 339, 172-4	3.3	45
56	The temporal localization of frame-shift ubiquitin-B and amyloid precursor protein, and complement proteins in the brain of non-demented control patients with increasing Alzheimer's disease pathology. <i>Neuroscience Letters</i> , 2003 , 348, 46-50	3.3	17
55	Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003 , 24, 521-36	5.6	208
54	Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. <i>Brain Research Bulletin</i> , 2003 , 61, 243-53	3.9	63
53	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. <i>Journal of Psychiatric Research</i> , 2002 , 36, 131-5	5.2	21
52	Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. <i>Neuropsychopharmacology</i> , 2002 , 27, 638-45	8.7	52
51	Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. <i>Annals of Neurology</i> , 2002 , 52, 253-6	9.4	130
50	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. <i>Psychophysiology</i> , 2002 , 39, 175-181	4.1	93

49	High-resolution peptide mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central nervous system diseases. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 782, 353-61	3.2	20
48	Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. <i>Archives of Neurology</i> , 2002 , 59, 1267-72		225
47	Progression of corpus callosum atrophy in Alzheimer disease. <i>Archives of Neurology</i> , 2002 , 59, 243-8		139
46	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2002 , 194, 15-9	3.2	40
45	Prefrontal cortex modulation of mood and emotionally induced facial expressions: a transcranial magnetic stimulation study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001 , 13, 206-12	2.7	24
44	Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 24-8	5.1	9
43	Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. <i>Glia</i> , 2001 , 35, 72-9	9	315
42	Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. <i>Annals of Neurology</i> , 2001 , 50, 150-6	9.4	195
41	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. <i>Annals of Neurology</i> , 2001 , 49, 545-546	9.4	89
40	CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. <i>Molecular Neurobiology</i> , 2001 , 24, 87-97	6.2	186
39	No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosis. <i>Neuroscience Letters</i> , 2001 , 305, 13-6	3.3	7
38	Severe hirsutism associated with psychopharmacological treatment in major depression. <i>World Journal of Biological Psychiatry</i> , 2001 , 2, 48-9	3.8	1
37	Physiology and biochemistry of the interleukin-6 receptor complex: Implications for CNS disorders and Alzheimer's disease 2001 , 121-143		6
36	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 2001 , 49, 545		1
35	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000 , 12, 391-394	3.4	8
34	Alzheimer's disease, depression and normal ageing: merit of simple psychomotor and visuospatial tasks. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 31-9	3.9	7
33	Corpus callosum measurement as an in vivo indicator for neocortical neuronal integrity, but not white matter pathology, in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 470-6	6.5	13
32	The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. <i>International Journal of Psychophysiology</i> , 2000 , 37, 87-98	2.9	51

31	Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. <i>Neuroscience Letters</i> , 2000 , 284, 113-5	3.3	33
30	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2000 , 287, 187-90	3.3	151
29	Polymorphisms in the alpha-2 macroglobulin gene in psychogeriatric patients. <i>Neuroscience Letters</i> , 2000 , 294, 69-72	3.3	10
28	Inflammation and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000 , 21, 383-421	5.6	3490
27	Pisa Syndrome (Pleurothotonus). <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 569-574	4.6	38
26	Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. <i>Alzheimer Disease and Associated Disorders</i> , 1999 , 13, 9-19	2.5	48
25	CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1999 , 99, 218-23	3.5	60
24	Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. <i>Brain Research</i> , 1999 , 823, 104-12	3.7	73
23	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. <i>Neuroscience Letters</i> , 1999 , 259, 145-8	3.3	50
22	Cerebrospinal fluid tau protein shows a better discrimination in young old (. <i>Neuroscience Letters</i> , 1999 , 277, 21-4	3.3	55
21	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. <i>Psychiatry Research</i> , 1999 , 88, 163-71	9.9	235
20	Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. <i>Archives of Neurology</i> , 1999 , 56, 467-73		46
19	Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz 1999 , 153-166		
18	Cholinerge Behandlungsstrategien 1999 , 179-190		1
17	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. <i>Brain Research</i> , 1998 , 780, 356-9	3.7	47
16	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. <i>Human Psychopharmacology</i> , 1998 , 13, 43-51	2.3	3
15	Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator mader in normal human CNS. <i>NeuroImmunoModulation</i> , 1998 , 5, 270-6	2.5	8
14	Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis. <i>Archives of Neurology</i> , 1998 , 55, 193-8		150

13	Detection of the novel cell adhesion molecule MUC18 in human brain tissue. <i>NeuroImmunoModulation</i> , 1997 , 4, 57-61	2.5	7
12	Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. <i>Alzheimer Disease and Associated Disorders</i> , 1997 , 11, 78-87	2.5	46
11	Frequency variation of a pattern-flash visual stimulus during PET differentially activates brain from striate through frontal cortex. <i>NeuroImage</i> , 1997 , 5, 116-28	7.9	63
10	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1997 , 228, 143-6	3.3	55
9	Unstable anticoagulation in the course of amitriptyline treatment. <i>Pharmacopsychiatry</i> , 1996 , 29, 33-7	2	4
8	Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. <i>Schizophrenia Research</i> , 1996 , 19, 103-9	3.6	81
7	Psychodrug-induced and EDTA associated thrombocytopenia: important factors in the differential diagnosis of low platelet counts. <i>European Psychiatry</i> , 1996 , 11, 416-8	6	
6	CNS demyelination in monoclonal gammopathy of undetermined significance (MGUS): possible cause of a dementia syndrome. <i>European Psychiatry</i> , 1996 , 11, 46-9	6	1
5	Modified oral anticoagulant potency in an amitriptyline-treated patient?. <i>Acta Haematologica</i> , 1996 , 96, 178-80	2.7	3
4	A case of Ganser's state presenting as a dementia syndrome. <i>Psychopathology</i> , 1996 , 29, 236-41	3.4	14
3	Expression of T cell receptor gamma delta antigens in human brain tissue. <i>NeuroImmunoModulation</i> , 1995 , 2, 115-20	2.5	11
2	Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995 , 6, 348-54	2.6	15
1	Expression of human heat-shock protein 70 antigens and gamma/delta T-cell receptor antigens in human central nervous tissue. <i>Annals of the New York Academy of Sciences</i> , 1994 , 741, 305-15	6.5	2